Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Frölich L, Johnson G, Patel K, Arciola B, Mhaskar R, Wood A, Schmidt C, Albanyan O, Gödel P, Hoster E, Bullinger L, Mackensen A, Locke F, von Bergwelt M, Barba P, Subklewe M, Jain MD. Bücklein V, et al. Among authors: johnson g. Hemasphere. 2023 Jul 11;7(8):e907. doi: 10.1097/HS9.0000000000000907. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37449196 Free PMC article.
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M. Rejeski K, et al. Among authors: johnson g. J Immunother Cancer. 2022 May;10(5):e004475. doi: 10.1136/jitc-2021-004475. J Immunother Cancer. 2022. PMID: 35580927 Free PMC article.
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL.
Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier CA, Chavez JC, Shah BD, Khimani F, Nishihori T, Lazaryan A, Davila ML, Mhaskar R, Locke FL, Gaballa S, Jain MD. Perez A, et al. Among authors: johnson g. Blood Adv. 2022 Jul 12;6(13):3970-3973. doi: 10.1182/bloodadvances.2022007006. Blood Adv. 2022. PMID: 35816359 Free PMC article. No abstract available.
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Wood AC, et al. Among authors: johnson g. Transplant Cell Ther. 2022 Dec;28(12):829.e1-829.e8. doi: 10.1016/j.jtct.2022.09.009. Epub 2022 Sep 26. Transplant Cell Ther. 2022. PMID: 36174934 Free PMC article.
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going.
Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM, Riaz IB, Andrews JR, Thorpe MP, Johnson GB, Kendi AT, Kwon ED, Nauseef JT, Morgans AK, Sartor O, Childs DS. Muniz M, et al. Among authors: johnson gb. Cancer Treat Rev. 2024 Apr 30;127:102748. doi: 10.1016/j.ctrv.2024.102748. Online ahead of print. Cancer Treat Rev. 2024. PMID: 38703593 Review.
Toxic household exposures in children.
King K, Smith R, Johnson G. King K, et al. Among authors: johnson g. BMJ. 2024 May 3;385:e077046. doi: 10.1136/bmj-2023-077046. BMJ. 2024. PMID: 38702067 No abstract available.
6,436 results